All Episodes – Page 7

SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr

SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized cont

Audio Journal of Oncology Podcast December, 2024: Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia Hua Zhang MD PhD (Chief Scientific Officer with S

BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United King

Amy A. Kirkwood MSc

Don't Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia

Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best p

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical

An interview with: Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, from the Yonsei Cancer Center at Yonsei University College of Medicine in Seoul, South Korea. BARCELONA, Spain—A “next gen

ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine

Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i

BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and

New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma Interview with: Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona a

PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immu

BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were

HEIDELBERG, Germany—André Pfob, Clinical Research Assistant from the University Breast Unit at Heidelberg University Hospital, Germany tells the Audio Journal of Oncology’s correspondent Peter

PARIS, France—Long remissions and potential cures were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancer

ATLANTA, USA—A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into acute myeloid leukemia. Fin

PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of t